Comparative Pharmacology
Head-to-head clinical analysis: BUTABARBITAL SODIUM versus PENTOBARBITAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTABARBITAL SODIUM versus PENTOBARBITAL SODIUM.
BUTABARBITAL SODIUM vs PENTOBARBITAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.
Enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors, prolonging chloride channel opening and inhibiting neuronal firing.
Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.
Induction of anesthesia: 100-150 mg IV given over 30-60 seconds; additional increments of 25-50 mg as needed. Hypnotic/sedative: 100-300 mg IM or 150-200 mg PO at bedtime. Anticonvulsant in emergencies: 5-7 mg/kg IV slow push over 1-2 minutes, may repeat every 15-30 minutes up to a maximum of 1 g. Rectal administration: 120-200 mg as a single dose for sedation.
None Documented
None Documented
Terminal elimination half-life: 30-50 hours; accumulates with repeated dosing, prolonged in hepatic impairment
Terminal elimination half-life of 20-30 hours in adults. In prolonged ICU sedation, context-sensitive half-life can extend significantly (up to 50-100 hours) due to redistribution and accumulation.
Renal: 50-70% as metabolites (hydroxylated and conjugated forms), 5-10% unchanged; fecal: minor (<5%)
Primarily renal excretion of inactive metabolites (hepatic metabolism via CYP). Approximately 25-50% unchanged in urine at alkaline pH; biliary/fecal elimination minimal (<5%).
Category C
Category D/X
Barbiturate
Barbiturate